Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod

Cindy Berthelot; Mary C Dickerson; Peter Rady; Qin He; Farhad Niroomand; Stephen K Tyring; Amit G Pandya

doi:10.1016/j.jaad.2007.01.036

Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod

J Am Acad Dermatol. 2007 May;56(5):882-6. doi: 10.1016/j.jaad.2007.01.036. Epub 2007 Mar 26.

Authors

Cindy Berthelot¹, Mary C Dickerson, Peter Rady, Qin He, Farhad Niroomand, Stephen K Tyring, Amit G Pandya

Affiliation

¹ Medical School, University of Texas Southwestern Medical Center at Dallas, USA.

PMID: 17368633
DOI: 10.1016/j.jaad.2007.01.036

Abstract

Epidermodysplasia verruciformis (EV) is a rare disorder characterized by widespread human papillomavirus infection and malignant transformation. EV may be caused by mutations of the genes EVER1 or EVER2, which are located on the EV1 locus, 17q25. We describe a patient with EV and a novel homozygous gene mutation of EVER2 gene who was treated successfully with topical imiquimod.

Publication types

Case Reports

MeSH terms

Administration, Topical
Adult
Aminoquinolines / administration & dosage*
Antineoplastic Agents / administration & dosage*
Carcinoma, Basal Cell / etiology
Carcinoma, Basal Cell / pathology
Carcinoma, Basal Cell / therapy
Carcinoma, Squamous Cell / etiology
Carcinoma, Squamous Cell / pathology
Carcinoma, Squamous Cell / therapy
Epidermodysplasia Verruciformis / complications
Epidermodysplasia Verruciformis / genetics*
Epidermodysplasia Verruciformis / therapy*
Humans
Imiquimod
Male
Membrane Proteins / genetics*
Mutation
Skin Neoplasms / etiology*
Skin Neoplasms / pathology
Skin Neoplasms / therapy

Substances

Aminoquinolines
Antineoplastic Agents
Membrane Proteins
TMC8 protein, human
Imiquimod